Fulcrum Therapeutics Inc — Cash Flow (NASDAQ:FULC) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 53.66 M78.48 M97.05 M90.97 M2.22 M60.06 M 60.06 M Cash from investing activities 57.14 M129.67 M12.41 M36.69 M32.23 M30.72 M 30.72 M Cash from financing activities 71.13 M186.51 M84.32 M118.12 M2.75 M168.67 M 168.67 M Free cash flow 52.31 M76.77 M95.09 M90.46 M1.94 M59.75 M 59.75 M

News

Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC)

Fulcrum Therapeutics stock falls as sickle cell trial misses target

Leerink reiterates Fulcrum Therapeutics stock rating on SCD data

BofA reiterates Fulcrum Therapeutics stock Underperform rating at $7

Stifel reiterates Fulcrum Therapeutics stock rating on drug data

Fulcrum Therapeutics shares fall on profit-taking, Oppenheimer says

Fulcrum Therapeutics stock tumbles despite trial results

Fulcrum reports positive trial results for sickle cell treatment

What's Going On With Fulcrum Therapeutics Stock Tuesday? - Fulcrum Therapeutics (NASDAQ:FULC)

Fulcrum to present 12-week results from sickle cell disease trial

Wall Street Analysts See a 75.71% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?

Fulcrum Therapeutics, Inc. (FULC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript